Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleSystematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Comprehensive Treatment of Dactylitis in Psoriatic Arthritis

Shawn Rose, Sergio Toloza, Wilson Bautista-Molano and Philip S. Helliwell on behalf of the GRAPPA Dactylitis Study Group
The Journal of Rheumatology November 2014, 41 (11) 2295-2300; DOI: https://doi.org/10.3899/jrheum.140879
Shawn Rose
From the US National Institutes of Health, Bethesda, Maryland, USA; Rheumatology, Ministry of Health, San Fernando del Valle de Catamarca, Argentina; Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG, Bogotá, Colombia; University of Leeds, Leeds; and Bradford Hospitals NHS Foundation Trust, Bradford, UK.
S. Rose, MD, PhD, Metzger Clinical Scholar, National Institutes of Health; S. Toloza, MD, Rheumatology, Ministry of Health; W. Bautista-Molano, MD, PhD(c), Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG; P.S. Helliwell, DM, PhD, FRCP, Senior Lecturer in Rheumatology, University of Leeds and Bradford Hospitals NHS Foundation Trust. Drs. Rose and Toloza contributed equally to this report.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio Toloza
From the US National Institutes of Health, Bethesda, Maryland, USA; Rheumatology, Ministry of Health, San Fernando del Valle de Catamarca, Argentina; Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG, Bogotá, Colombia; University of Leeds, Leeds; and Bradford Hospitals NHS Foundation Trust, Bradford, UK.
S. Rose, MD, PhD, Metzger Clinical Scholar, National Institutes of Health; S. Toloza, MD, Rheumatology, Ministry of Health; W. Bautista-Molano, MD, PhD(c), Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG; P.S. Helliwell, DM, PhD, FRCP, Senior Lecturer in Rheumatology, University of Leeds and Bradford Hospitals NHS Foundation Trust. Drs. Rose and Toloza contributed equally to this report.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilson Bautista-Molano
From the US National Institutes of Health, Bethesda, Maryland, USA; Rheumatology, Ministry of Health, San Fernando del Valle de Catamarca, Argentina; Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG, Bogotá, Colombia; University of Leeds, Leeds; and Bradford Hospitals NHS Foundation Trust, Bradford, UK.
S. Rose, MD, PhD, Metzger Clinical Scholar, National Institutes of Health; S. Toloza, MD, Rheumatology, Ministry of Health; W. Bautista-Molano, MD, PhD(c), Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG; P.S. Helliwell, DM, PhD, FRCP, Senior Lecturer in Rheumatology, University of Leeds and Bradford Hospitals NHS Foundation Trust. Drs. Rose and Toloza contributed equally to this report.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip S. Helliwell
From the US National Institutes of Health, Bethesda, Maryland, USA; Rheumatology, Ministry of Health, San Fernando del Valle de Catamarca, Argentina; Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG, Bogotá, Colombia; University of Leeds, Leeds; and Bradford Hospitals NHS Foundation Trust, Bradford, UK.
S. Rose, MD, PhD, Metzger Clinical Scholar, National Institutes of Health; S. Toloza, MD, Rheumatology, Ministry of Health; W. Bautista-Molano, MD, PhD(c), Department of Rheumatology, Hospital Militar Central, Faculty of Medicine UMNG; P.S. Helliwell, DM, PhD, FRCP, Senior Lecturer in Rheumatology, University of Leeds and Bradford Hospitals NHS Foundation Trust. Drs. Rose and Toloza contributed equally to this report.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: p.helliwell@leeds.ac.uk

Abstract

Dactylitis, a hallmark clinical feature of psoriatic arthritis (PsA) and other spondyloarthropathies, may also be a severity marker for PsA and psoriasis. Traditionally, clinicians have used nonsteroidal antiinflammatory drugs and local corticosteroid injections to treat dactylitis, although conventional disease-modifying antirheumatic drugs are also used. We performed a systematic literature review to determine the most efficacious current treatment options for dactylitis in PsA. Effect sizes were greatest for the biologic agents ustekinumab, certolizumab, and infliximab, suggesting that therapy with one of these agents should be initiated in patients with dactylitis. However, the limited data highlight the need for randomized, placebo-controlled trials, with dactylitis as a primary outcome, to determine a valid, reliable, and responsive clinical outcome measure for PsA patients with dactylitis.

Key Indexing Terms:
  • PSORIATIC ARTHRITIS
  • DACTYLITIS
  • TREATMENT
  • SYSTEMATIC REVIEW

Dactylitis, or “sausage digit,” is considered a hallmark clinical feature of psoriatic arthritis (PsA) and other spondyloarthropathies1. The diagnosis of dactylitis, however, is challenging for clinicians not familiar with it, and is frequently misdiagnosed in cases of mild dactylitis, in obese patients, and in those with severe overlying psoriatic skin disease. Other causes of dactylitis include trauma, fracture, gout, sepsis, sarcoidosis, and tuberculosis. In cases of diagnostic uncertainty, magnetic resonance imaging (MRI) and ultrasound may help to discriminate dactylitic digits from normal ones2.

The treatment of dactylitis has largely remained empirical. Nonsteroidal antiinflammatory drugs (NSAID) are usually employed initially, but many rheumatologists rapidly progress to injected corticosteroids, which are supported by clinical evidence of response in patients with mild to moderate PsA. In resistant cases, disease-modifying antirheumatic drugs (DMARD) are used with or without biologic agents. Comparative effectiveness of these treatment strategies has not been systematically studied.

The focus of our review is to identify and evaluate the effects of therapeutic interventions used to treat dactylitis in patients with PsA. The review is part of a treatment update initiated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Search strategy

Ovid Medline was searched from 1966 to the present, using the search terms “dactylitis” (as key search word) and “psoriatic arthritis” (treatment only). Only randomized, double-blind placebo-controlled (RCT) or open-label trials of PsA in which dactylitis was assessed as a separate outcome measure were identified. Thus, 74 articles (English-language reports only) were identified, and 29 articles were selected for full review3-13,14-24,25,26,27,28,29,30,31.

Two reviewers (SR and ST) independently extracted the data regarding study design, sample size, duration, population, agents, outcome measures, outcome data, p value, and effect size using a standardized data extraction form. A third reviewer (PH) resolved differences if needed. A fourth reviewer (WBM) examined safety data pertaining to the use of DMARD and biologic agents.

RESULTS

Of the 29 trials that assessed dactylitis as an outcome measure, a total of 6589 adult patients with PsA were studied for 12 weeks to 60 months (Table 1)3-13,14-24,25,26,27,28,29,30,31. Several studies (n = 18) were RCT with crossover design at 12–24 weeks, with or without open-label extensions. One study was prospective from a historical cohort (10 years), another was a prospective followup case-control study, and the remaining 9 were open-label studies.

View this table:
  • View inline
  • View popup
Table 1.

Summary of clinical therapeutic studies with dactylitis as a primary or secondary outcome.

Of the 29 studies, 22 were multicenter with participation from North America, Europe, the Middle East, South Africa, Latin America, and Asia-Pacific countries. The remaining studies were single-center: 1 each from Canada, Italy, and Germany; and 2 each from Greece and the United Kingdom.

Therapeutic interventions were heterogeneous and included DMARD (methotrexate, hydroxychloroquine, leflunomide, cyclosporin A, and sulfasalazine), biologics (certolizumab, ustekinumab, golimumab, adalimumab, etanercept, infliximab, and anakinra), and the oral phosphodiesterase 4 inhibitor apremilast.

Dactylitis outcome measures were also heterogeneous and included the number of dactylitic digits (maximum 20 digits; either tender and/or nontender on 0–3 scale), percentage of patients with dactylitis, Leeds Dactylitis Index and its simplified version (LDI, LDI basic), and MRI dactylitis scores. Some studies used a simple count of dactylitic digits (based on clinician opinion), while others graded the severity 0–3 or 1–4, and all 20 digits were counted. No studies of local steroid injections or NSAID were identified.

Because of the large variability in study designs and outcome measures, and poor availability of primary data, a metaanalysis could not be performed. Significant improvement (p < 0.05) in dactylitis compared to placebo was observed with the use of certolizumab in the RAPID-PsA trial4 and with ustekinumab in the PSUMMIT1 trial6; in Phase II studies, with the use of golimumab in the GO-REVEAL trials8,9; with infliximab in the IMPACT121 and IMPACT222 trials; with a combination of infliximab plus methotrexate compared to methotrexate alone in an open-label study11; and with the use of adalimumab in prior treatment failures in other open-label studies7,15.

In contrast, no significant benefit was demonstrated in RCT of apremilast (PALACE)3, or adalimumab (ADEPT)19, or an open-label adalimumab trial23; with the use of leflunomide (TOPAS)28, or with the use of sulfasalazine in a multicenter study of US veterans31.

Although an etanercept study (PRESTA) demonstrated improvement in dactylitis scores16, a placebo-controlled trial with dactylitis as an endpoint is required. Elsewhere, the role of anakinra is still uncertain14.

Measures of treatment effect

In the few cases where primary data were available, we calculated the effect sizes for the various therapeutic interventions used in the 29 included trials (Table 1). The best available data from RCT suggested that infliximab (effect size 0.41, IMPACT1)21, certolizumab (effect size 0.50, RAPID-PsA)4, and ustekinumab (effect size 0.29, pooled PSUMMIT1 and PSUMMIT2 data)5,6 were likely to be efficacious, while effect sizes for leflunomide and sulfasalazine were 0.33 and 0.2, respectively, despite no significant difference between the treatment and placebo arms in these 2 studies28,31.

Toxicity/safety aspects related to dactylitis

A review of toxicity/safety data revealed no evidence of adverse events related to dactylitis itself. Adverse events were those typically seen in trials of either psoriasis or PsA (i.e., liver toxicity, gastrointestinal manifestations, exacerbation of psoriasis, and incidence of malignancies and autoimmune diseases).

DISCUSSION

Conclusions and limitations

This brief review reveals the dearth of evidence for treating dactylitis in patients with PsA, with highly variable study designs, dactylitis assessments, and patient populations. The most commonly used therapies, NSAID and local corticosteroid injections, have not been formally assessed. DMARD alone may be mildly effective, but the trials have not been adequately powered. Apremilast demonstrated no significant benefit.

Of the biologic drugs tested, only ustekinumab, certolizumab, and infliximab seemed promising, with golimumab as another potential candidate. Etanercept requires more dedicated study to ascertain its efficacy, and adalimumab may be ineffective. The roles of anakinra and newer small molecules and biologic therapies are uncertain.

Because dactylitis may represent a composite of pathological features, it could be argued that an assessment of tenderness and swelling in the component parts (proximal interphalangeal joint and distal interphalangeal joint) is sufficient. However, important and potentially clinically-relevant information could be lost in this simplistic definition. Imaging studies have indicated that dactylitis is a complex, multicompartment disorder, with features including tenosynovitis, enthesitis, osteitis, synovitis, capsulitis, and soft-tissue swelling32. The clinical utility of inflammatory markers and imaging studies to distinguish hot versus cold dactylitis also deserves careful scrutiny. A clear understanding of onset, duration, persistence, anatomical location (hands vs feet), and morphology will be required. Further, the training of dermatologists and other clinicians to recognize and assess dactylitis will be important not only for future clinical trials, but also to hasten referral to a rheumatologist in community practice.

Given the importance and frequency of dactylitis in PsA, future studies should include both robust and quantifiable clinical indices (e.g., the LDI), as well as imaging modalities (e.g., MRI and ultrasound), the latter of which are particularly promising as valid and sensitive measures to assess dactylitis. Importantly, future investigations using dactylitis as a primary outcome measure will determine the most appropriate treatment for this painful and damaging condition.

Acknowledgment

The authors acknowledge Laura Coates for conducting a review of the English-language dactylitis studies, Hans-Georg Zmierczak and Amir Haddad for examining dactylitis studies published in languages other than English, and Claudia Schainberg for reviewing the Juvenile PsA literature. The members of the GRAPPA Dactylitis Working Group also deserve recognition for helpful comments and suggestions pertaining to the manuscript.

APPENDIX 1

List of study collaborators. GRAPPA Dactylitis Working Group (in addition to authors listed): Ade Adebajo, UK; Sueli Carneiro, Brazil; Amir Haddad, Canada; Gurjit Kaeley, USA; Shelley Kafka, USA; Anna Moverley, UK; Oleg Nadashkevich, Ukraine; Andrew Parkinson (patient representative), UK; Ruben Queiro, Spain; Claudia Schainberg, Brazil; Ulku Ucar, Turkey; Rafael Valle-Oñate, Colombia; Hans-Georg Zmierczak, Belgium.

REFERENCES

  1. 1.
    1. Moll JM,
    2. Wright V
    . Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55–78.
  2. 2.
    1. Bakewell CJ,
    2. Olivieri I,
    3. Aydin SZ,
    4. Dejaco C,
    5. Ikeda K,
    6. Gutierrez M,
    7. et al.
    Ultrasound and magnetic resonance imaging in the evaluation of psoriatic dactylitis: Status and perspectives. J Rheumatol 2013;40:1951–7.
  3. 3.
    1. Kavanaugh A,
    2. Mease PJ,
    3. Gomez-Reino JJ,
    4. Adebajo AO,
    5. Wollenhaupt J,
    6. Gladman DD,
    7. et al.
    Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020–6.
  4. 4.
    1. Mease PJ,
    2. Fleischmann R,
    3. Deodhar AA,
    4. Wollenhaupt J,
    5. Khraishi M,
    6. Kielar D,
    7. et al.
    Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48–55.
  5. 5.
    1. Ritchlin C,
    2. Rahman P,
    3. Kavanaugh A,
    4. McInnes IB,
    5. Puig L,
    6. Li S,
    7. et al.
    Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990–9.
  6. 6.
    1. McInnes IB,
    2. Kavanaugh A,
    3. Gottlieb AB,
    4. Puig L,
    5. Rahman P,
    6. Ritchlin C,
    7. et al.
    Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780–9.
  7. 7.
    1. Gladman DD,
    2. Ziouzina O,
    3. Thavaneswaran A,
    4. Chandran V
    . Dactylitis in psoriatic arthritis: Prevalence and response to therapy in the biologic era. J Rheumatol 2013;40:1357–9.
  8. 8.
    1. Kavanaugh A,
    2. van der Heijde D,
    3. McInnes IB,
    4. Mease P,
    5. Krueger GG,
    6. Gladman DD,
    7. et al.
    Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504–17.
  9. 9.
    1. Kavanaugh A,
    2. Mease P
    . Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol Suppl 2012;89:90–3.
  10. 10.
    1. Cantini F,
    2. Niccoli L,
    3. Cassara E,
    4. Kaloudi O,
    5. Nannini C
    . Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term follow-up study. Biologics 2012;6:201–6.
  11. 11.
    1. Baranauskaite A,
    2. Raffayova H,
    3. Kungurov NV,
    4. Kubanova A,
    5. Venalis A,
    6. Helmle L,
    7. et al.
    Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: The RESPOND study. Ann Rheum Dis 2012;71:541–8.
  12. 12.
    1. Saougou I,
    2. Markatseli TE,
    3. Papagoras C,
    4. Voulgari PV,
    5. Alamanos Y,
    6. Drosos AA
    . Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: A 5-year open-label observational cohort study. Semin Arthritis Rheum 2011;40:398–406.
  13. 13.
    1. Karanikolas GN,
    2. Koukli EM,
    3. Katsalira A,
    4. Arida A,
    5. Petrou D,
    6. Komninou E,
    7. et al.
    Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: Results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011;38:2466–74.
  14. 14.
    1. Jung N,
    2. Hellmann M,
    3. Hoheisel R,
    4. Lehmann C,
    5. Haase I,
    6. Perniok A,
    7. et al.
    An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010;29:1169–73.
  15. 15.
    1. Gladman DD,
    2. Sampalis JS,
    3. Illouz O,
    4. Guerette B
    . Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: Effectiveness and safety results from an open-label study. J Rheumatol 2010;37:1898–906.
  16. 16.
    1. Sterry W,
    2. Ortonne JP,
    3. Kirkham B,
    4. Brocq O,
    5. Robertson D,
    6. Pedersen RD,
    7. et al.
    Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.
  17. 17.
    1. Kavanaugh A,
    2. McInnes I,
    3. Mease P,
    4. Krueger GG,
    5. Gladman D,
    6. Gomez-Reino J,
    7. et al.
    Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976–86.
  18. 18.
    1. Gottlieb A,
    2. Menter A,
    3. Mendelsohn A,
    4. Shen YK,
    5. Li S,
    6. Guzzo C,
    7. et al.
    Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633–40.
  19. 19.
    1. Mease PJ,
    2. Ory P,
    3. Sharp JT,
    4. Ritchlin CT,
    5. Van den Bosch F,
    6. Wellborne F,
    7. et al.
    Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702–9.
  20. 20.
    1. Healy PJ,
    2. Groves C,
    3. Chandramohan M,
    4. Helliwell PS
    . MRI changes in psoriatic dactylitis — extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology 2008;47:92–5.
  21. 21.
    1. Antoni CE,
    2. Kavanaugh A,
    3. van der Heijde D,
    4. Beutler A,
    5. Keenan G,
    6. Zhou B,
    7. et al.
    Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869–76.
  22. 22.
    1. Kavanaugh A,
    2. Krueger GG,
    3. Beutler A,
    4. Guzzo C,
    5. Zhou B,
    6. Dooley LT,
    7. et al.
    Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498–505.
  23. 23.
    1. Genovese MC,
    2. Mease PJ,
    3. Thomson GT,
    4. Kivitz AJ,
    5. Perdok RJ,
    6. Weinberg MA,
    7. et al.
    Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040–50.
  24. 24.
    1. Healy PJ,
    2. Helliwell PS
    . Measuring dactylitis in clinical trials: Which is the best instrument to use? J Rheumatol 2007;34:1302–6.
  25. 25.
    1. Antoni CE,
    2. Kavanaugh A,
    3. Kirkham B,
    4. Tutuncu Z,
    5. Burmester GR,
    6. Schneider U,
    7. et al.
    Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227–36.
  26. 26.
    1. Antoni C,
    2. Krueger GG,
    3. de Vlam K,
    4. Birbara C,
    5. Beutler A,
    6. Guzzo C,
    7. et al.
    Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150–7.
  27. 27.
    1. Mease PJ,
    2. Gladman DD,
    3. Ritchlin CT,
    4. Ruderman EM,
    5. Steinfeld SD,
    6. Choy EH,
    7. et al.
    Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279–89.
  28. 28.
    1. Kaltwasser JP,
    2. Nash P,
    3. Gladman D,
    4. Rosen CF,
    5. Behrens F,
    6. Jones P,
    7. et al.
    Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939–50.
  29. 29.
    1. Salvarani C,
    2. Cantini F,
    3. Olivieri I,
    4. Macchioni P,
    5. Padula A,
    6. Niccoli L,
    7. et al.
    Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003;49:541–5.
  30. 30.
    1. Salvarani C,
    2. Macchioni P,
    3. Olivieri I,
    4. Marchesoni A,
    5. Cutolo M,
    6. Ferraccioli G,
    7. et al.
    A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28:2274–82.
  31. 31.
    1. Clegg DO,
    2. Reda DJ,
    3. Mejias E,
    4. Cannon GW,
    5. Weisman MH,
    6. Taylor T,
    7. et al.
    Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013–20.
  32. 32.
    1. Kaeley GS
    . Ultrasound imaging module: Report from the GRAPPA 2012 annual meeting. J Rheumatol 2013;40:1450–2.

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire